Dr Simona Soverini is an Assistant Professor at the Department of Experimental, Diagnostic and Specialty Medicine of the University of Bologna, in Italy. Dr Soverini graduated with a degree in Biological Sciences in 1999 and subsequently earned a PhD in Clinical and Experimental Haematology from the University of Bologna. She currently works in the Molecular Biology Unit of the Institute of Hematology “Lorenzo e Ariosto Seragnoli”, where she coordinates the Myeloid Leukemia Research group. Since 2003, her main interests lie in the biology and therapy of chronic myeloid leukaemia (CML) and Philadelphia chromosome-positive acute lymphoblast leukaemia (ALL), with a particular focus on the mechanisms of resistance to tyrosine kinase inhibitors. In this field, she has worked with many internationally renowned scientists and has earned honours and awards. Over the past years, Dr Soverini has also cultivated a growing interest in the application of novel technologies as diagnostic tools. Dr Soverini has participated as an invited speaker or chairperson in more than two hundred national and international meetings. She sits in the Editorial Board of the Journal of Hematology & Oncology, the International Journal of Molecular Sciences and Stem Cell Investigation. She also serves as a reviewer for journals like Blood, Leukemia, Haematologica and Clinical Cancer Research, for the European Hematology Association (EHA) and for the American Society of Hematology (ASH). As an active member of the European LeukemiaNet, she has coordinated the panel of CML experts that in 2011 compiled the recommendations for BCR ABL1 kinase domain mutation analysis in CML patients treated with tyrosine kinase inhibitors. Dr Soverini is the first or contributing author of over 150 publications in international peer reviewed journals (H-index, 46) and of over 500 meeting abstracts.